Verve

IMPROVING HEMP YIELDS TO INCREASE PROFTABILITY FOR FARMERS

Retrieved on: 
Thursday, April 4, 2024
Dicarboxylic acid, Farmer, Grain, Growth, Rotation, FHF, The Honourable, Economic development, CBD, Health Canada, FBN, Parity, Breeding, HGI, Farmers Business Network, Verve, Agriculture

During the five-year project, partners will work to position hemp as a protein-rich crop with increased yields and expanded ingredient and food usages.

Key Points: 
  • During the five-year project, partners will work to position hemp as a protein-rich crop with increased yields and expanded ingredient and food usages.
  • “Improving the yield of hemp increases the profitability of the crop, bringing benefit to farmers, while also bringing more healthy and sustainable high-protein options for ingredient manufacturers and food processors.”
    Fresh Hemp Foods, Farmer’s Business Network Canada and Verve are industry leaders in their respective fields.
  • FBN manages hybrid canola and hemp breeding programs and together with Verve has the largest hemp seed genetics portfolio in North America.
  • Fresh Hemp Foods, established in 1998, is a global leader in contract hemp production, food ingredient processing and hemp-based consumer packaged goods.

Attention Verve Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Tuesday, April 2, 2024
Bloomberg, News, Therapy, Verve, Pharmaceutical industry

​LOS ANGELES, April 02, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Verve Therapeutics, Inc. (“Verve” or “the Company”) (NASDAQ: VERV) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Verve stock. Verve investors are encouraged to contact the firm to discuss their legal rights.

Key Points: 
  • ​LOS ANGELES, April 02, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Verve Therapeutics, Inc. (“Verve” or “the Company”) (NASDAQ: VERV) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Verve stock.
  • Verve investors are encouraged to contact the firm to discuss their legal rights.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Retrieved on: 
Tuesday, April 2, 2024
Bloomberg, Suite, Ethics, News, Verve, Security (finance)

LOS ANGELES, April 02, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. (“Verve” or “the Company”) (NASDAQ: VERV ) for violations of the securities laws.

Key Points: 
  • LOS ANGELES, April 02, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. (“Verve” or “the Company”) (NASDAQ: VERV ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
Beam Therapeutics, Research, PCSK9, American Heart Association, Gene editing, Eli Lilly and Company, Blood, FDA, AHA, N-Acetylgalactosamine, Cardiovascular disease, Food, Verve, Safety, RNA, Vertex Pharmaceuticals, Therapy, Genetics, Lilly, Patient, LPA, Medicine, Clinical trial, ANGPTL3, Apolipoprotein, Science, LDLR, G&A, IND, Asialoglycoprotein receptor, Moyamoya disease, Human, Beam, Pharmaceutical industry

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported pipeline updates and financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported pipeline updates and financial results for the fourth quarter and year ended December 31, 2023.
  • “2023 was a momentous year for Verve as we made significant strides towards our mission of protecting the world from cardiovascular disease.
  • Verve expects to initiate the VERVE-201 Phase 1b clinical trial in the second half of 2024, subject to regulatory clearances.
  • In October 2023 , Verve announced the expansion of its relationship with Lilly, which was previously established in June 2023.

Verve Motion Unveils Integrated Software and Data Analytics Platform to Elevate Industrial Worker Safety and Operations with its Wearable Robotics Exosuit

Retrieved on: 
Wednesday, March 6, 2024
Robotics, Powered exoskeleton, Doctor of Philosophy, Workplace, Posture, Research, Peter Hancock (professor), 3D, Injury, Harvard University, Verve, Risk, Feedback, Safety, Health, Faculty, Lifting, Organization, Facility, Logic, Workforce, Motion, Environment, Software, Mobile phone

Verve Logic™ software and data analytics platform paves the way for game-changing enhancements in industrial worker safety when used in combination with SafeLift™ exosuit solution.

Key Points: 
  • Verve Logic™ software and data analytics platform paves the way for game-changing enhancements in industrial worker safety when used in combination with SafeLift™ exosuit solution.
  • The combination of a software platform and unique data analytics, which build off industry standard risk factors, provides ergonomic-based insights for individual worker safety metrics.
  • CAMBRIDGE, Mass., March 6, 2024 /PRNewswire/ -- In a significant stride toward shaping the future of industrial safety, Verve Motion today introduced a software and data analytics platform, Verve Logic™, seamlessly integrated into its innovative wearable robotics SafeLift™ exosuit.
  • Now available as a standard feature with the SafeLift exosuit, the Verve Logic platform delivers cutting-edge safety analytics.

Aktiia Secures CHF 27 Million (USD 30M) in Funding from Khosla Ventures and Others, Welcomes Daniel Graf as New President and Board Member to Accelerate Innovation in Hypertension Management

Retrieved on: 
Tuesday, February 27, 2024
Blood pressure, USD, Entrepreneurship, Uber, Heart rate, Daniel, CHF, Verve, Death, Data, Khosla Ventures, Hypertension, Health, Deep learning, Research, Pharmaceutical industry

In conjunction with this funding, Aktiia is delighted to welcome Daniel Graf as its new President and Board Member.

Key Points: 
  • In conjunction with this funding, Aktiia is delighted to welcome Daniel Graf as its new President and Board Member.
  • Daniel, a seasoned technology executive with a distinguished career at companies like Uber and Google, brings a wealth of experience in entrepreneurship, product innovation, and scaling businesses.
  • His leadership will be instrumental in guiding Aktiia's strategic direction and expansion as the company continues to pioneer advancements in hypertension management.
  • "We are proud to have Daniel join our board and executive team," said Mattia Bertschi, CEO of Aktiia.

Aktiia Secures CHF 27 Million (USD 30M) in Funding from Khosla Ventures and Others, Welcomes Daniel Graf as New President and Board Member to Accelerate Innovation in Hypertension Management

Retrieved on: 
Tuesday, February 27, 2024
Blood pressure, USD, Entrepreneurship, Uber, Heart rate, Daniel, CHF, Verve, Death, Data, Khosla Ventures, Hypertension, Health, Deep learning, Research, Pharmaceutical industry

In conjunction with this funding, Aktiia is delighted to welcome Daniel Graf as its new President and Board Member.

Key Points: 
  • In conjunction with this funding, Aktiia is delighted to welcome Daniel Graf as its new President and Board Member.
  • Daniel, a seasoned technology executive with a distinguished career at companies like Uber and Google, brings a wealth of experience in entrepreneurship, product innovation, and scaling businesses.
  • His leadership will be instrumental in guiding Aktiia's strategic direction and expansion as the company continues to pioneer advancements in hypertension management.
  • "We are proud to have Daniel join our board and executive team," said Mattia Bertschi, CEO of Aktiia.

Verve Cloud, Inc. Earns 2024 Great Place to Work Certification™

Retrieved on: 
Tuesday, January 16, 2024
Cloud, Certification, Unified communications, SAN, Culture, Trust, Verve, OTCQB

“We are thrilled to be certified as a Great Place To Work™ for the 5th year in a row.

Key Points: 
  • “We are thrilled to be certified as a Great Place To Work™ for the 5th year in a row.
  • The Great Place to Work Certification™ is based on results of the Trust Index™ survey administered by the Great Place to Work Institute, which assesses employee satisfaction in key areas, from credibility and respect to fairness and camaraderie.
  • “We are honored and excited to be recognized as a great place to work because it’s based on the dedication and commitment of our team members,” stated Patti Cuthill, VP of People & Culture at Verve.
  • At Verve, we strive for an inclusive and caring workplace where everyone is respected, valued, and empowered to do their best.”

Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement

Retrieved on: 
Wednesday, November 29, 2023
Telephone, ATTN:, Verve, Sale, Jefferies Group, BMO Capital Markets, Attention, RBC Capital Markets, William Blair & Company, Eli Lilly and Company, Vesey Street, Floor, Prospectus, Madison Avenue, Cardiovascular disease, Guggenheim Partners, Equity capital markets, Security (finance), Exercise

All of the shares in the public offering are being sold by Verve.

Key Points: 
  • All of the shares in the public offering are being sold by Verve.
  • In addition, Verve has granted the underwriters a 30-day option to purchase up to 1,875,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.
  • The public offering and concurrent private placement are expected to close on December 1, 2023, subject to the satisfaction of customary closing conditions.
  • Jefferies, Guggenheim Securities, William Blair, BMO Capital Markets, and RBC Capital Markets are acting as joint book-running managers for the public offering.

Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

Retrieved on: 
Tuesday, November 28, 2023
Telephone, Lilly, ATTN:, Verve, Sale, Jefferies Group, BMO Capital Markets, Attention, Jefferies, RBC Capital Markets, William Blair & Company, Eli Lilly and Company, Vesey Street, Floor, Prospectus, Madison Avenue, Cardiovascular disease, Equity capital markets, Security (finance), Guggenheim Partners, Exercise

In addition, Verve expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, Verve expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions.
  • The shares will be sold to Lilly at a price per share equal to the public offering price.
  • The proposed public offering and concurrent private placement are subject to market and other conditions, and there can be no assurance as to whether or when the public offering and concurrent private placement may be completed, or as to the actual size or terms of the public offering and concurrent private placement.
  • Jefferies, Guggenheim Securities, William Blair, BMO Capital Markets, and RBC Capital Markets are acting as joint book-running managers for the public offering.